It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Type 1 diabetes is a chronic autoimmune disease which results in inefficient regulation of glucose homeostasis and can lead to different vascular comorbidities through life. In this study we aimed to analyse the circulating miRNA expression profile of patients with type 1 diabetes, and with no other associated pathology. For this, fasting plasma was obtained from 85 subjects. Next generation sequencing analysis was firstly performed to identify miRNAs that were differentially expressed between groups (20 patients vs. 10 controls). hsa-miR-1-3p, hsa-miR-200b-3p, hsa-miR-9-5p, and hsa-miR-1200 expression was also measured by Taqman RT-PCR to validate the observed changes (34 patients vs. 21 controls). Finally, through a bioinformatic approach, the main pathways affected by the target genes of these miRNAs were studied. Among the studied miRNAs, hsa-miR-1-3p expression was found significantly increased in patients with type 1 diabetes compared to controls, and positively correlated with glycated haemoglobin levels. Additionally, by using a bioinformatic approach, we could observe that changes in hsa-miR-1-3p directly affect genes involved in vascular development and cardiovascular pathologies. Our results suggest that, circulating hsa-miR-1-3p in plasma, together with glycaemic control, could be used as prognostic biomarkers in type 1 diabetes, helping to prevent the development of vascular complications in these patients.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Health Research Institute of the Principality of Asturias (ISPA), Endocrinology, Nutrition, Diabetes and Obesity Group (ENDO), Oviedo, Spain (GRID:grid.511562.4); Instituto de Salud Carlos III, Centre for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain (GRID:grid.413448.e) (ISNI:0000 0000 9314 1427)
2 Health Research Institute of the Principality of Asturias (ISPA), Endocrinology, Nutrition, Diabetes and Obesity Group (ENDO), Oviedo, Spain (GRID:grid.511562.4); University of Barcelona, Barcelona, Spain (GRID:grid.5841.8) (ISNI:0000 0004 1937 0247)
3 Health Research Institute of the Principality of Asturias (ISPA), Endocrinology, Nutrition, Diabetes and Obesity Group (ENDO), Oviedo, Spain (GRID:grid.511562.4); Asturias Central University Hospital, Endocrinology and Nutrition Department, Oviedo, Spain (GRID:grid.411052.3) (ISNI:0000 0001 2176 9028); University of Oviedo, Medicine Department, Oviedo, Spain (GRID:grid.10863.3c) (ISNI:0000 0001 2164 6351)
4 Health Research Institute of the Principality of Asturias (ISPA), Endocrinology, Nutrition, Diabetes and Obesity Group (ENDO), Oviedo, Spain (GRID:grid.511562.4); Asturias Central University Hospital, Endocrinology and Nutrition Department, Oviedo, Spain (GRID:grid.411052.3) (ISNI:0000 0001 2176 9028)
5 Health Research Institute of the Principality of Asturias (ISPA), Endocrinology, Nutrition, Diabetes and Obesity Group (ENDO), Oviedo, Spain (GRID:grid.511562.4)
6 Instituto de Salud Carlos III, Centre for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain (GRID:grid.413448.e) (ISNI:0000 0000 9314 1427); Health Research Institute of Asturias (ISPA), Nanomaterials and Nanotechnology Research Center (CINN-CSIC), Oviedo, Spain (GRID:grid.511562.4); Institute of Oncology of Asturias (IUOPA), Oviedo, Spain (GRID:grid.511562.4); University of Oviedo, Department of Organisms and Systems Biology (B.O.S), Oviedo, Spain (GRID:grid.10863.3c) (ISNI:0000 0001 2164 6351)
7 Health Research Institute of the Principality of Asturias (ISPA), Endocrinology, Nutrition, Diabetes and Obesity Group (ENDO), Oviedo, Spain (GRID:grid.511562.4); Instituto de Salud Carlos III, Centre for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain (GRID:grid.413448.e) (ISNI:0000 0000 9314 1427); Asturias Central University Hospital, Endocrinology and Nutrition Department, Oviedo, Spain (GRID:grid.411052.3) (ISNI:0000 0001 2176 9028); University of Oviedo, Medicine Department, Oviedo, Spain (GRID:grid.10863.3c) (ISNI:0000 0001 2164 6351)